Anakinra as a diagnostic challenge and treatment option for systemic autoinflammatory disorders of undefined etiology.

ABSTRACT:

Background

Some adult patients presenting with unexplained pyrexia, serositis, skin rashes, arthralgia, myalgia, and other symptoms commonly found in autoinflammatory disorders may not fit a specific diagnosis, either because their clinical phenotype is nondiagnostic or genetic tests are negative. We used the term undifferentiated systemic autoinflammatory disorder (uSAID) to describe such cases. Given that well-defined autoinflammatory diseases show responses to IL-1 blockade, we evaluated whether anakinra was useful for both diagnosing and treating uSAID patients.

Methods

We performed a retrospective analysis of consecutive patients presenting with uSAID between 2012-2015 who were treated with the recombinant IL-1 receptor antagonist anakinra. uSAID was diagnosed after exc

SUBMITTER: Harrison SR 

PROVIDER: S-EPMC5033915 | biostudies-literature | 2016 May

REPOSITORIES: biostudies-literature